comparemela.com

Latest Breaking News On - Preserved ejection fraction - Page 1 : comparemela.com

Heart failure: Ozempic, Wegovy may improve symptoms, aid weight loss

Heart failure: Ozempic, Wegovy may improve symptoms, aid weight loss
medicalnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalnewstoday.com Daily Mail and Mail on Sunday newspapers.

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Tenax Therapeutics Announces New U S Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Announces New U S Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Beta-blockers do not lower mortality after myocardial infarction with preserved ejection fraction

1. In this randomized controlled trial, long-term beta-blockers did not impact all-cause mortality among patients with preserved left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) and early angiography. 2. Long-term beta-blocker therapy was not associated with a higher risk of adverse events compared to no beta-blocker. Evidence Rating Level: 1 (Excellent) Study

Semaglutide improves obesity-related heart failure symptoms

1. In this randomized controlled trial, semaglutide was more effective in reducing heart failure-related symptoms and physical limitations in patients with obesity-related heart failure and type 2 diabetes mellitus (T2DM) than placebo. 2. Patients with obesity-related heart failure and T2DM exhibited greater weight loss with semaglutide than placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Heart

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.